User:BrianF4/sandbox

From Wikipedia, the free encyclopedia
"Inah" redirects here. For "INAH", see Instituto Nacional de Antropología e Historia.
Isoniazid
Clinical data
Trade namesHydra, Hyzyd, Isovit, others
Other namesisonicotinic acid hydrazide, isonicotinyl hydrazine, INHA
AHFS/Drugs.comMonograph
MedlinePlusa682401
License data
Pregnancy
category
Routes of
administration		By mouth, intramuscular, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingVery low (0–10%)
Metabolismliver; CYP450: 2C19, 3A4 inhibitor
Elimination half-life0.5–1.6h (fast acetylators), 2-5h (slow acetylators)
Excretionurine (primarily), feces
Identifiers
  • Pyridine-4-carbohydrazide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
Chemical and physical data
FormulaC6H7N3O
Molar mass137.139 g/mol g·mol−1
3D model (JSmol)
  • C1=CN=CC=C1C(=O)NN
  • InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10) checkY
  • Key:QRXWMOHMRWLFEY-UHFFFAOYSA-N checkY
  (verify)

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis.[2] For active tuberculosis it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol.[3] For latent tuberculosis it is often used by itself.[2] It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi.[2] It is usually taken by mouth but may be used by injection into muscle.[2]

Common side effect include increased blood levels of liver enzymes and numbness in the hands and feet.[2] Serious side effects may include liver inflammation and acute liver failure.[2] It is unclear if use during pregnancy is safe for the baby.[4] Use during breastfeeding is likely safe.[4] Pyridoxine may be given to reduce the risk of side effects.[5] Isoniazid works in part by disrupting the formation of the bacteria's cell wall which results in cell death.[2]

Isoniazid was first made in 1952.[6] It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[7] Isoniazid is available as a generic medication.[2] The wholesale cost in the developing world is about US$0.60–4.75 per month.[8] In the United States a month of treatment costs less than $25.[5]

Medical uses[edit]

Tuberculosis[edit]

Isoniazid is often used to treat latent and active tuberculosis infections. In persons with isoniazid-sensitive Mycobacterium tuberculosis infection, drug regimens based on isoniazid are usually effective when persons adhere to the prescribed treatment. However, in persons with isoniazid-resistant Mycobacterium tuberculosis infection, drug regimens based on isoniazid have a high rate of failure.[9]

Isoniazid has been approved as prophylatic therapy for the following populations:

  • People with HIV infection and a PPD (purified protein derivative) reaction of at least 5 mm induration
  • Contacts of people with tuberculosis and who have a PPD reaction at least 5 mm induration
  • People whose PPD reactions convert from negative to positive in a two-year period – at least 10 mm induration for those up to 35 years of age, and at least 15 mm induration for those at least 35 years old
  • People with pulmonary damage on their chest X-ray that is likely to be due to healed tuberculosis and also have a PPD reaction at least 5 mm induration
  • Injection drug users whose HIV status is negative who have a PPD reaction at least 10 mm induration
  • People with a PPD of greater than or equal to 10 mm induration who are foreign-born from high prevalence geographical regions, low-income populations, and patients residing in long-term facilities[10][11]

Isoniazid can be used alone or in combination with Rifampin for treatment of latent tuberculosis, or as part of a four-drug regimen for treatment of active tuberculosis.[12] The drug regimen typically requires daily or weekly oral administration for a period of three to nine months, often under Directly Observed Therapy (DOT) supervision.[12]

Non-tuberculous mycobacteria[edit]

Isoniazid was widely used in the treatment of Mycobacterium avium complex as part of a regimen including rifampicin and ethambutol.[13] Evidence suggests that isoniazid prevents mycolic acid synthesis in M. avium complex as in M. tuberculosis[14] and although this is not bactericidal to M. avium complex, it greatly potentiates the effect of rifampicin. The introduction of macrolides led to this use greatly decreasing. However, since rifampicin is broadly underdosed in M. avium complex treatment this effect may be worth re-investigating.[15]

Special populations[edit]

It is recommended that women with active tuberculosis who are pregnant or breastfeeding take isoniazid. Preventive therapy should be delayed until after giving birth.[16] Nursing mothers excrete a relatively low and non-toxic concentration of INH in breast milk, and their babies are at low risk for side effects. Both pregnant women and infants being breastfed by mothers taking INH should take vitamin B6 in its pyridoxine form to minimize the risk of peripheral nerve damage.[17] Vitamin B6 is used to prevent isoniazid-induced B6 deficiency and neuropathy in people with a risk factor, such as pregnancy, lactation, HIV infection, alcoholism, diabetes, kidney failure, or malnutrition.[18]

People with liver dysfunction are at a higher risk for hepatitis caused by INH, and may need a lower dose.[16]

Levels of liver enzymes in the bloodstream should be frequently checked in daily alcohol drinkers, pregnant women, IV drug users, people over 35, and those who have chronic liver disease, severe kidney dysfunction, peripheral neuropathy, or HIV infection since they are more likely to develop hepatitis from INH.[16][19]

Side effects[edit]

Up to 20% of people taking isoniazid experience peripheral neuropathy when taking doses of 6 mg/kg of weight daily or higher.[20] Gastrointestinal reactions include nausea and vomiting.[10] Aplastic anemia, thrombocytopenia, and agranulocytosis due to lack of production of red blood cells, platelets, and white blood cells by the bone marrow respectively, can also occur.[10] Hypersensitivity reactions are also common and can present with a maculopapular rash and fever.[10] Gynecomastia may occur.[12]

Headache, poor concentration, weight gain, poor memory, insomnia, and depression have all been associated with isoniazid use.[21] All patients and healthcare workers should be aware of these serious side effects, especially if suicidal ideation or behavior are suspected.[21][22][23]

Isoniazid is associated with pyridoxine (vitamin B6) deficiency because of its similar structure. Isoniazid is also associated with increased excretion of pyridoxine. Pyridoxal phosphate (a derivative of pyridoxine) is required for δ-aminolevulinic acid synthase, the enzyme responsible for the rate-limiting step in heme synthesis. Therefore, isoniazid-induced pyridoxine deficiency causes insufficient heme formation in early red blood cells, leading to sideroblastic anemia.[18]

Asymptomatic elevation of serum liver enzyme concentrations occurs in 10% to 20% of people taking INH, and liver enzyme concentrations usually return to normal even when treatment is continued.[24] Isoniazid has a boxed warning for severe and sometimes fatal hepatitis, which is age-dependent at a rate of 0.3% in people 21 to 35 years old and over 2% in those over age 50.[10][25] Symptoms suggestive of liver toxicity include nausea, vomiting, abdominal pain, dark urine, right upper quadrant pain, and loss of appetite.[10] Black and Hispanic women are at higher risk for isoniazid-induced hepatotoxicity.[10] When it happens, isoniazid-induced liver toxicity has been shown to occur in 50% of patients within the first 2 months of therapy.[26]

Some recommend that liver function should be monitored carefully in all people receiving it,[16] but others recommend monitoring only in certain populations.[24][27][28]. Isoniazid consumption is associated with hepatotoxicity and is seen with transient elevation of serum alanine aminotransferase (ALT) levels with minimal increases in alkaline phosphatase (ALP) levels.[29] Some patients (<1-3%) may develop severe liver injury and liver failure.[29] Elevation in levels of ALT and aspartate aminotransferase (AST) can vary between 1 week to 9 months following isonizaid treatment.[30] Histological characteristics of hepatotoxicity show liver cell injury with multilobular necrosis and a mononuclear cell infiltrate. [30]

Long term use of isoniazid may lead to a lupus-like autoimmune response in the presence of antinuclear antibodies.[30]

Drug interactions[edit]

People taking isoniazid and acetominophen are at risk of acetaminophen toxicity. Isoniazid is thought to induce a liver enzyme which causes a larger amount of acetaminophen to be metabolized to a toxic form.[31][32]

Isoniazid decreases the metabolism of carbamazepine, thus slowing down its clearance from the body. People taking carbamazepine should have their carbamazepine levels monitored and, if necessary, have their dose adjusted accordingly.[33]

It is possible that isoniazid may decrease the serum levels of ketoconazole after long-term treatment. This is seen with the simultaneous use of rifampin, isoniazid, and ketoconazole.[34]

Isoniazid may increase the amount of phenytoin in the body. The doses of phenytoin may need to be adjusted when given with isoniazid.[35][36]

Isoniazid may increase the plasma levels of theophylline. There are some cases of theophylline slowing down isoniazid elimination. Both theophylline and isoniazid levels should be monitored.[37]

Valproate levels may increase when taken with isoniazid. Valproate levels should be monitored and its dose adjusted if necessary.[35]

Mechanism of action[edit]

Isoniazid is a prodrug that inhibits the formation of the mycobacterial cell wall. Isoniazid must be activated by KatG, a bacterial catalase-peroxidase enzyme in Mycobacterium tuberculosis.[38] KatG catalyzes the formation of the isonicotinic acyl radical, which spontaneously couples with NADH to form the nicotinoyl-NAD adduct. This complex binds tightly to the enoyl-acyl carrier protein reductase InhA, thereby blocking the natural enoyl-AcpM substrate and the action of fatty acid synthase. This process inhibits the synthesis of mycolic acids, which are required components of the mycobacterial cell wall. A range of radicals are produced by KatG activation of isoniazid, including nitric oxide,[39] which has also been shown to be important in the action of another antimycobacterial prodrug pretomanid.[40]

Isoniazid (INH) is activated by KatG to the isonicotinic acyl radical, which subsequently reacts with NAD to form the isonicotinic acyl-NADH complex.

Isoniazid is bactericidal to rapidly dividing mycobacteria, but is bacteriostatic if the mycobacteria are slow-growing.[41] It inhibits the cytochrome P450 system and hence acts as a source of free radicals.[42]

Isoniazid is a mild monoamine oxidase inhibitor(MAO-I).[43]

Metabolism[edit]

Isoniazid reaches therapeutic concentrations in serum, cerebrospinal fluid, and within caseous granulomas. It is metabolized in the liver via acetylation into acetylhydrazine. Two forms of the enzyme are responsible for acetylation, so some patients metabolize the drug more quickly than others. Hence, the half-life is bimodal, with "slow acetylators" and "fast acetylators". A graph of number of people versus time shows peaks at one and three hours. The height of the peaks depends on the ethnicities of the people being tested. The metabolites are excreted in the urine. Doses do not usually have to be adjusted in case of renal failure.

N-acetyltransferases (NATs) are involved in the acetylation of arylamines from acetyl-CoA, and as such is involved in the acetylation of INH.[29] NAT1 and NAT2 are two of the major N-acetyltransferases; NAT1 is expressed in all tissues while NAT2 expression is limited to the liver and the gastrointestinal tract. NAT2 is the dominant enzyme involved acetylating isoniazid, hydrazine (Hz), and acetylhydrazine (AcHz).[29] NAT2 functions in INH deactivation through the acetylation of isoniazid (AcINH formation).[29] NAT2 acetylation of hydrazine (AcHz formation) leads to INH bioactivation.[29] NAT2 also acetylates AcHz (DiAcHz formation), which leads to INH detoxification in the liver.[29] However, the role of NAT2 in INH induced hepatotoxicity is not well understood and requires further research.[29]

Amidases catalyze the hydrolysis of amides and are directly involved in metabolizing INH to isonicotinic acid (INA) and hydrazine, as well as hydrolysis AcINH and AcHz.[29]. Since Hz and AcHz act as hepatotoxic metabolites of INH, higher amidase activities can result in greater chances of INH induced hepatotoxicity.

Cytochrome P450 (P450) may be involved in hepatotoxicity, as it is involved in the oxidation of Hz and AcHz to reactive metabolites.[29] It is also known to be involved in the direct activation of isoniazid.[29]

Glutathione S-transferases (GSTs) may be involved in prevention of hepatotoxicity, as it may detoxify the reactive metabolites produced by the oxidation of Hz and AcHz. Further studies must be done to identify the detoxified metabolites.[29]

History[edit]

Initial Synthesis[edit]

Isonicotinic acid hydrazide was first synthesized in 1912 with ethyl isonicotinate and hydrazine.[44]

Clinical Use[edit]

Isoniazid's use as a drug for treating tuberculosis was only later discovered upon testing of amithiozone as a potential anti-tuberculosis drug, in 1952[45]. However, clinical tests of amithiozone was found to have complicated side effects in patients[45]. Other drugs such as pyrazinamide were potential drug candidates, but M.tuberculosis could quickly gain resistance to it, making it ineffective for treatment of tuberculosis[46]. Conversely, isoniazid was found to be not only effective as an antitubercular compound, but also selective for mycobacteria[45].

Three pharmaceutical companies unsuccessfully attempted to patent the drug at the same time,[47] the most prominent one being Roche, which launched its version, Rimifon, in 1952.[48] With the introduction of isoniazid, a cure for tuberculosis was first considered possible.

The drug was first tested at Many Farms, a Navajo community in Arizona, due to the Navajo reservation's tuberculosis problem and because the population had not previously been treated with streptomycin, the main tuberculosis treatment at the time.[49] The research was led by Walsh McDermott, an infectious disease researcher with an interest in public health, who had previously taken isoniazid to treat his own tuberculosis.[50]

Isoniazid and a related drug, iproniazid, were among the first drugs to be referred to as antidepressants.[51]

Biochemical Properties[edit]

In 1970, isoniazid was discovered to inhibit mycolic acids in M.tuberculosis[52]. Mycolic acid inhibition was discovered to be correlated to cell death of M.tuberculosis, in 1972[53]. In 1992, mutations in katG, the gene that encodes catalase-peroxidase, in M.tuberculosis resulted in resistance to isoniazid[54]. Isoniazid is a prodrug that is activated by catalase-peroxidase, consistent with mycobacteria conferring resistance to isoniazid following katG mutations [55].

Synthesis[edit]

Isoniazid is an isonicotinic acid derivative. It is manufactured using 4-cyanopyridine and hydrazine hydrate.[56] In the proposed synthesis, 4-cyanopyridine is converted into isonicotinamide through addition of water. Isonicotinamide reacts with hydrazine to form isoniazid.


In another method, isoniazid was claimed to have been made from citric acid starting material.[57]

Brand names[edit]

Hydra, Hyzyd, Isovit, Laniazid, Nydrazid, Rimifon, and Stanozide.[58]

Other uses[edit]

Chromatography[edit]

Isonicotinic acid hydrazide is also used in chromatography to differentiate between various degrees of conjugation in organic compounds barring the ketone functional group.[59] The test works by forming a hydrazone which can be detected by its bathochromic shift.

Dogs[edit]

Isoniazid may be used for dogs, but there have been concerns it can cause seizures.[60]

References[edit]

  1. ^ a b "Isoniazid (Nydrazid) Use During Pregnancy". Drugs.com. 7 October 2019. Retrieved 24 January 2020.
  2. ^ a b c d e f g h i "Isoniazid". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  3. ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 136. hdl:10665/44053. ISBN 9789241547659.
  4. ^ a b "Isoniazid (Nydrazid) Use During Pregnancy". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
  5. ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 49. ISBN 9781284057560.
  6. ^ Walker, S. R. (2012). Trends and Changes in Drug Research and Development. Springer Science & Business Media. p. 109. ISBN 9789400926592. Archived from the original on 2017-09-10.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ "Isoniazid". International Drug Price Indicator Guide. Retrieved 8 December 2016.
  9. ^ Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D (February 2017). "Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis". Lancet Infect Dis. 17 (2): 223–234. doi:10.1016/S1473-3099(16)30407-8. PMID 27865891.
  10. ^ a b c d e f g "Isoniazid (package insert)".
  11. ^ "The Use of Preventive Therapy for Tuberculosis Infection in the United States – Recommendations of the Advisory Committee for Elimination of Tuberculosis". Morbidity and Mortality Weekly Report. 39 (RR-8): 9–12. May 18, 1990. Archived from the original on 2 March 2016. Retrieved 22 February 2016.
  12. ^ a b c Lewis, Sharon Mantik (5 December 2013). Medical-surgical nursing : assessment and management of clinical problems. Dirksen, Shannon Ruff,, Heitkemper, Margaret M. (Margaret McLean),, Bucher, Linda,, Harding, Mariann (Ninth ed.). St. Louis, Missouri. ISBN 978-0-323-10089-2. OCLC 228373703.{{cite book}}: CS1 maint: location missing publisher (link)
  13. ^ Research Committee of the British Thoracic Society (2001). "First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: Rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol". Thorax. 56 (3): 167–72. doi:10.1136/thorax.56.3.167. PMC 1758783. PMID 11182006.
  14. ^ Mdluli, K; Swanson, J; Fischer, E; Lee, R. E; Barry Ce, 3rd (1998). "Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium". Molecular Microbiology. 27 (6): 1223–33. doi:10.1046/j.1365-2958.1998.00774.x. PMID 9570407. S2CID 13764717.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  15. ^ Van Ingen, J; Egelund, E. F; Levin, A; Totten, S. E; Boeree, M. J; Mouton, J. W; Aarnoutse, R. E; Heifets, L. B; Peloquin, C. A; Daley, C. L (2012). "The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment". American Journal of Respiratory and Critical Care Medicine. 186 (6): 559–65. doi:10.1164/rccm.201204-0682OC. PMID 22744719.
  16. ^ a b c d "Isoniazid tablet". DailyMed. 18 October 2018. Archived from the original on 13 March 2019. Retrieved 24 January 2020.
  17. ^ Bothamley, G. (2001). "Drug treatment for tuberculosis during pregnancy: safety considerations". Drug Safety. 24 (7): 553–565. doi:10.2165/00002018-200124070-00006. PMID 11444726. S2CID 10479433.
  18. ^ a b Steichen, O.; Martinez-Almoyna, L.; De Broucker, T. (April 2006). "Isoniazid induced neuropathy: consider prevention" (PDF). Revue des Maladies Respiratoires. 23 (2 Pt 1): 157–160. doi:10.1016/S0761-8425(06)71480-2. PMID 16788441.
  19. ^ Saukkonen, J.J.; Cohn, D.L.; Jasmer, R.M. (October 15, 2006). "An official ATS statement: hepatotoxicity of antituberculosis therapy". American Journal of Respiratory and Critical Care Medicine. 174 (8): 935–952. doi:10.1164/rccm.200510-1666ST. PMID 17021358. S2CID 36384722.
  20. ^ Alldredge, Brian (February 12, 2013). Applied Therapeutics. ISBN 9781609137137.
  21. ^ a b Alao A.O.; Yolles J.C. (September 1998). "Isoniazid-induced psychosis". Annals of Pharmacotherapy. 32 (9): 889–891. doi:10.1345/aph.17377. PMID 9762376. S2CID 73122253.
  22. ^ Iannaccone, R.; Sue, Y.J.; Avner, J.R. (2002). "Suicidal psychosis secondary to isoniazid". Pediatric Emergency Care. 18 (1): 25–27. doi:10.1097/00006565-200202000-00008. PMID 11862134. S2CID 31383347.
  23. ^ Pallone K.A.; Goldman M.P.; Fuller M.A. (February 1993). "Isoniazid-associated psychosis: case report and review of the literature". Annals of Pharmacotherapy. 27 (2): 167–170. doi:10.1177/106002809302700205. PMID 8439690. S2CID 28637999.
  24. ^ a b "Latent Tuberculosis Infection: A Guide for Primary Health Care Providers". cdc.gov. Center for Disease Control. Archived from the original on 25 March 2016. Retrieved 25 March 2016.
  25. ^ Trevor, A. & Katzung, B. (2013). Katzung & Trevor's Pharmacology: examination & board review (10th ed., p. 417). New York. McGraw-Hill Medical, Lange.
  26. ^ "Isoniazid UpToDate". Archived from the original on 2015-10-25.
  27. ^ "Treatment of Tuberculosis – Guidelines (4th ed.)" (PDF). who.int. World Health Organization. Archived (PDF) from the original on 4 April 2016. Retrieved 25 March 2016.
  28. ^ "Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society". Thorax. 53 (7): 536–548. July 1998. doi:10.1136/thx.53.7.536. PMC 1745276. PMID 9797751.
  29. ^ a b c d e f g h i j k l Wang, Pengcheng; Pradhan, Komal; Zhong, Xiao-bo; Ma, Xiaochao (September 2016). "Isoniazid metabolism and hepatotoxicity". Acta Pharmaceutica Sinica B. 6 (5): 384–392. doi:10.1016/j.apsb.2016.07.014. PMC 5045547. PMID 27709007.
  30. ^ a b c Metushi, Imir; Uetrecht, Jack; Phillips, Elizabeth (June 2016). "Mechanism of isoniazid-induced hepatotoxicity: then and now". British Journal of Clinical Pharmacology. 81 (6): 1030–1036. doi:10.1111/bcp.12885. PMC 4876174. PMID 26773235.
  31. ^ Murphy, R.; Swartz, R.; Watkins, P.B. (November 15, 1990). "Severe acetaminophen toxicity in a patient receiving isoniazid". Annals of Internal Medicine. 113 (10): 799–800. doi:10.7326/0003-4819-113-10-799. PMID 2240884.
  32. ^ Burk, R.F.; Hill, K.E.; Hunt Jr., R.W.; Martin, A.E. (July 1990). "Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazole inhibition of it". Research Communications in Chemical Pathology and Pharmacolog. 69 (1): 115–118. PMID 2218067.
  33. ^ Fleenor, M.E.; Harden, J.W.; Curtis, G. (June 1991). "Interaction between carbamazepine and antituberculosis agents". Chest. 99 (6): 1554. doi:10.1378/chest.99.6.1554a. PMID 2036861.
  34. ^ Baciewicz, A.M.; Baciewicz Jr., F.A. (September 13, 1993). "Ketoconazole and fluconazole drug interactions". Archives of Internal Medicine. 153 (17): 1970–1976. doi:10.1001/archinte.153.17.1970. PMID 8357281.
  35. ^ a b Jonville, A.P.; Gauchez, A.S.; Autret, E.; Billard, C.; Barbier, P.; Nsabiyumva, F.; Breteau, M. (1991). "Interaction between isoniazid and valproate: a case of valproate overdosage". European Journal of Clinical Pharmacology. 40 (2): 197–198. doi:10.1007/BF00280078. PMID 2065702. S2CID 22218366.
  36. ^ Bass, Jr., J.B.; Farer, L.S.; Hopewell, P.C.; O'Brien, R.; Jacobs, R.F.; Ruben, F.; Snider, Jr., D.E.; Thornton, G. (May 1994). "Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention". Am J Respir Crit Care Med. 149 (5): 1359–1374. doi:10.1164/ajrccm.149.5.8173779. PMID 8173779.
  37. ^ Höglund, P.; Nilsson, L.G.; Paulsen, O. (February 1987). "Interaction between isoniazid and theophylline". European Journal of Respiratory Diseases. 70 (2): 110–116. PMID 3817069.
  38. ^ Suarez, J.; Ranguelova, K.; Jarzecki, A.A.; et al. (March 2009). "An oxyferrous heme/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG)". The Journal of Biological Chemistry. 284 (11): 7017–7029. doi:10.1074/jbc.M808106200. PMC 2652337. PMID 19139099.
  39. ^ Timmins, G.S.; Master, S; Rusnak, F.; Deretic, V. (August 2004). "Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 48 (8): 3006–3009. doi:10.1128/AAC.48.8.3006-3009.2004. PMC 478481. PMID 15273113.
  40. ^ Singh, R.; Manjunatha, U.; Boshoff, H.I.; et al. (November 2008). "PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release". Science. 322 (5906): 1392–1395. Bibcode:2008Sci...322.1392S. doi:10.1126/science.1164571. PMC 2723733. PMID 19039139.
  41. ^ Ahmad, Z.; Klinkenberg, L.G.; Pinn, M.L.; et al. (2009). "Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug‐Tolerant, Not Drug‐Resistant, Mycobacterium tuberculosis in the Guinea Pig". The Journal of Infectious Diseases. 200 (7): 1136–1143. doi:10.1086/605605. PMID 19686043.
  42. ^ Harvey, Richard A.; Howland, Richard D.; Mycek, Mary Julia; Champe, Pamela C. (2006). Harvey, Richard A.; Champe, Pamela C. (eds.). Pharmacology. Vol. 864 (4th ed.). Lippincott Williams & Wilkins. ISBN 9780781741187.
  43. ^ Judd, F. K.; Mijch, A. M.; Cockram, A.; Norman, T. R. (1994). "Isoniazid and antidepressants: is there cause for concern?". International Clinical Psychopharmacology. 9 (2): 123–125. doi:10.1097/00004850-199400920-00009. ISSN 0268-1315. PMID 8056994.
  44. ^ "Untitled Document". web.stanford.edu. Retrieved 2020-05-03.
  45. ^ a b c Chakraborty, Sumit; Rhee, Kyu Y. (August 2015). "Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1". Cold Spring Harbor Perspectives in Medicine. 5 (8): a021147. doi:10.1101/cshperspect.a021147. ISSN 2157-1422. PMC 4526730. PMID 25877396.
  46. ^ Vilchèze, Catherine; Jacobs, Jr., William R. (October 2007). "The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics". Annual Review of Microbiology. 61 (1): 35–50. doi:10.1146/annurev.micro.61.111606.122346. ISSN 0066-4227. PMID 18035606.
  47. ^ Riede, Hans L. (2009). "Fourth-generation fluoroquinolones in tuberculosis". Lancet. 373 (9670): 1148–1149. doi:10.1016/S0140-6736(09)60559-6. PMID 19345815. S2CID 43789954.
  48. ^ "History". rocheusa.com. Roche USA. Archived from the original on 2007-12-12.
  49. ^ Jones, David S. (2002). "The Health Care Experiments at Many Farms: The Navajo, Tuberculosis, and the Limits of Modern Medicine, 1952–1962". Bulletin of the History of Medicine. 76 (4): 749–790. doi:10.1353/bhm.2002.0186. PMID 12446978. S2CID 30166423.
  50. ^ Beeson, Paul B. (1990). "Walsh McDermott". Biographical Memoirs: V.59. National Academies Press. pp. 282–307.
  51. ^ Moncrieff, Joanna (June 2008). "The creation of the concept of an antidepressant: an historical analysis". Social Science & Medicine. 66 (11): 2346–2355. doi:10.1016/j.socscimed.2008.01.047. ISSN 0277-9536. PMID 18321627.
  52. ^ Winder, F. G.; Collins, P. B. (1970-09-01). "Inhibition by Isoniazid of Synthesis of Mycolic Acids in Mycobacterium tuberculosis". Journal of General Microbiology. 63 (1): 41–48. doi:10.1099/00221287-63-1-41. ISSN 0022-1287. PMID 5500025.
  53. ^ Takayama, K.; Wang, L.; David, H. L. (1972-07-01). "Effect of Isoniazid on the In Vivo Mycolic Acid Synthesis, Cell Growth, and Viability of Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 2 (1): 29–35. doi:10.1128/AAC.2.1.29. ISSN 0066-4804. PMC 444261. PMID 4208567.
  54. ^ Zhang, Ying; Heym, Beate; Allen, Bryan; Young, Douglas; Cole, Stewart (August 1992). "The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis". Nature. 358 (6387): 591–593. doi:10.1038/358591a0. ISSN 0028-0836. PMID 1501713. S2CID 4366763.
  55. ^ Johnsson, Kai; Schultz, Peter G. (August 1994). "Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis". Journal of the American Chemical Society. 116 (16): 7425–7426. doi:10.1021/ja00095a063. ISSN 0002-7863.
  56. ^ William Andrew Publishing (2008). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Norwich, NY: Elsevier Science. pp. 1968–1970. ISBN 9780815515265.
  57. ^ Baizer, Manuel M.; Dub, Michael; Gister, Sidney; Steinberg, Nathan G. (1956). "Synthesis of Isoniazid from Citric Acid". Journal of the American Pharmaceutical Association (Scientific Ed.). 45 (7): 478–480. doi:10.1002/jps.3030450714. ISSN 0095-9553. PMID 13345683.
  58. ^ "Drugs@FDA". fda.gov. United States Food and Drug Administration. Archived from the original on 14 August 2012. Retrieved 22 August 2016.
  59. ^ Smith, L.L.; Foell, Theodore (1959). "Differentiation of Δ4-3-Ketosteroids and Δ1,4-3-Ketosteroids with Isonicotinic Acid Hydrazide". Analytical Chemistry. 31 (1): 102–105. doi:10.1021/ac60145a020.
  60. ^ Sykes, Jane E. (2013). Canine and Feline Infectious Diseases (E-Book). Elsevier Health Sciences. p. 425. ISBN 978-0323241946 – via Google Books.

Further reading[edit]

External links[edit]

  • "Isoniazid". Drug Information Portal. U.S. National Library of Medicine.

Category:Anti-tuberculosis drugs Category:Antidepressants Category:Disulfiram-like drugs Category:GABA transaminase inhibitors Category:Hepatotoxins Category:Hydrazides Category:Isonicotinamides Category:Prodrugs Category:Vitamin B6 antagonists Category:World Health Organization essential medicines

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:BrianF4/sandbox&oldid=1095042712"